Beginning Cash (Quarterly)

Beginning Cash: The amount of cash reported by the company on its previous statement.

BioCryst Pharmaceuticals, Inc. (BCRX) Beginning Cash data is not available for the most recently reported fiscal quarter, ending 2026-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2026-06-30

Income Statement Financials
Revenue	$218.25M
Net Income	$78.39M
Cost of Goods Sold	$3.84M
Gross Profit	$214.41M
Operating Expenses	$119.78M
Operating Income	$98.47M
Non-Operating Income/Expense	$-18.99M
Pre-Tax Income	$79.47M
Normalized Pre-Tax Income	$79.47M
Income after Taxes	$78.39M
Income from Continuous Operations	$78.39M
Consolidated Net Income/Loss	$78.39M
Normalized Income after Taxes	$78.39M
EBIT	$98.47M
EBITDA	$98.76M
Weighted-Average Shares Outstanding (Basic)	254.48M
Weighted-Average Shares Outstanding (Diluted)	265.17M
Earnings per Share (EPS) (Basic)	$0.31
Earnings per Share (EPS) (Diluted)	$0.30
Balance Sheet Financials
Current Assets	$484.68M
Property, Plant, and Equipment	$9.06M
Long-Term Assets	$73.17M
Total Assets	$557.85M
Current Liabilities	$208.85M
Long-Term Debt	$779.23M
Long-Term Liabilities	$803.29M
Total Liabilities	$1.01B
Common Equity	$-454.29M
Tangible Shareholders Equity	$-454.29M
Shareholders Equity	$-454.29M
Common Shares Outstanding	255.26M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$42.55M
Cash Flow from Investing Activities	$-378.80M
Cash Flow from Financial Activities	$401.40M
Beginning Cash	--
End Cash	$65.05M
Increase/Decrease in Cash	$65.05M
Stock-Based Compensation	$30.72M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.32
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	2.40
Debt to Equity Ratio	-1.85
Gross Margin	98.24%
Operating Margin	45.12%
EBIT Margin	45.12%
EBITDA Margin	--
Pre-Tax Profit Margin	36.41%
Profit Margin	35.92%
Free Cash Flow	$41.94M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.39
Inventory Turnover	0.63
Receiveable Turnover	1.97
Days Sales in Receivables	45.67
Return on Equity	-17.26%
Return on Tangible Equity	-17.26%
Return on Assets	14.05%
Return on Investments	24.13%
Book Value Per Share	$-1.78
Free Cash Flow per Share	$0.16
Operating Cash Flow per Share	$0.16

Data from Zacks Investment Research, Inc.